Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Half of the participants took a semaglutide tablet daily and half took a placebo. Participants continued their assigned regimen for an average of just under four years. By the end of the trial ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

More information: Meghan I. Podolsky et al, Factors Associated With Semaglutide Initiation Among Adults With Obesity, JAMA Network Open (2025). DOI: 10.1001/jamanetworkopen.2024.55222 Provided by ...

In India, there were 32 centres and 788 people enrolled. Semaglutide was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight ...